Navigation Links
MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
Date:9/19/2007

FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO Surgical Corp. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

All of the offered shares will be sold by MAKO Surgical Corp. The number of shares to be offered and the price range of the offering have not yet been determined. The Company intends to apply to have its common stock approved for quotation on the NASDAQ Global Market under the symbol "MAKO."

J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will act as joint bookrunners for the offering and Cowen and Company, LLC and Wachovia Capital Markets, LLC will act as co-lead managers. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its advanced robotic solution and implants for minimally invasive orthopedic knee procedures. MAKO's Haptic Guidance System(TM) includes an interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of resurfacing implants through a keyhole incision. This FDA-cleared surgeon- interactive haptic robotic system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. As of September 18, 2007, 80 MAKOplasty procedures have been performed since commercial introduction in June 2006. MAKO has an intellectual property portfolio of more than two hundred licensed or owned patent applications relating to the areas of computer assisted surgery, haptics, robotics, and implants.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


'/>"/>
SOURCE MAKO Surgical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
2. Surgical products company wins Governors Business Plan Contest
3. Vector Surgical hopes to turn frustration into faster surgeries
4. Metavante Corp. will continue M&A activity
5. Lucigen Corp. enters global licensing agreement
6. CIO Leadership Series: Jane Durment, Marcus Corp.
7. Brady Corp. acquires Korean counterpart
8. Brady Corp. raises $137 million in public offering
9. Symphony Corp. and CareEvolution to partner
10. RedPrairie Corp. introduces new supply chain software
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
(Date:6/23/2016)... ReportsnReports.com adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):